Alfa Cytology Announces Holistic Approach to RDC Development Services Supported by In Vivo Studies in Radiopharmaceuticals
Alfa Cytology has announced RDC development services supported by In Vivo studies in radiopharmaceuticals.
Alfa Cytology, a leading-edge biotech company engaged in cancer research, has released its services on robust RDC (Radionuclide Drug Conjugate) development technical support for radiopharmaceuticals. The services are specifically designed to transform the radiopharmaceutical industry, enhancing quality and precision for disease diagnosis and therapy.
The oncology and diagnostic imaging fields are rapidly expanding, with an increasing need for transformative approaches to medical research and treatment. As current methods in disease diagnosis and treatment often lack the specificity, sensitivity, and customization demanded by the cutting edge of diagnostic medicine and theranostics, Alfa Cytology has developed the platform to meet the individualized needs of its clients. This takes a highly individualized approach, accounting for the specific biochemical and kinetic characteristics of the large variety of radiotracers and therapeutics in use. Alfa Cytology's expert services can be leveraged for the custom synthesis, optimization, and quality control of radiopharmaceuticals, to a standard of safety and efficacy unequaled by other service providers.
An essential component is in vivo studies in radiopharmaceuticals. These studies, which give critical insights into the in vivo interactions and pharmacodynamics of radiopharmaceuticals, form the backbone of a rigorous approach to therapeutic radiopharmaceutical development. The research is supported by an extensive imaging and analytical infrastructure, enabling researchers to better understand the biodistribution, safety, pharmacokinetics, and overall therapeutic potential of next-generation radiopharmaceutical agents. The in vivo research option is a critical tool in efforts to develop more targeted and individualized radiopharmaceutical therapeutics and diagnostics.
Alfa Cytology offers a wide range of technical support options and expert services for research teams, including custom synthesis of radiotracers, radionuclide production, labeling methodologies, and advanced analytical support to maximize radiochemical purity, as well as radioanalytical support and method development.
Alfa Cytology continues to expand its service offerings and is continuously updating its highly experienced technical teams to meet the increasingly complex demands of the research community and to continue to be a resource for innovation and development in diagnostic imaging and cancer therapy. Alfa Cytology provides a fully integrated infrastructure to leverage RDC services and take advantage of cutting-edge in vivo research, connecting the laboratory to the real world.
About Alfa Cytology
Alfa Cytology, headquartered in New York, is a CRO company, offering state of the art solutions in radiopharmaceutical R&D. Alfa Cytology's team of industry veterans have assembled a set of broad integrated skills in molecular imaging, radiochemistry, and regulatory sciences, which allow them to provide next-generation services across the broad range of research needs within the community. For more information on the newest tools and solutions in radiopharmaceuticals, visit our service pages to learn how Alfa Cytology is redefining the future of cancer research and nuclear medicine.
Media Contact
Company Name: Alfa Cytology
Contact Person: Thassia C.
Email: Send Email
Country: United States
Website: https://www.alfacytology.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Alfa Cytology Announces Holistic Approach to RDC Development Services Supported by In Vivo Studies in Radiopharmaceuticals
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Geek Wire
24 minutes ago
- Geek Wire
ByteDance lays off 65 Seattle-area workers
(GeekWire File Photo / Todd Bishop) ByteDance, the Beijing-based parent company of TikTok, is laying off 65 workers based in Bellevue, Wash., according to a new filing with the Washington state Employment Security Department. ByteDance, Inc., is laying off 27 workers, while TikTok, Inc., is laying off 38 employees, according to the filing. The Chinese tech giant landed in the Seattle region in 2021 and has been growing its footprint in Amazon's backyard as it bolstered its TikTok Shop online shopping business. But TikTok has recently cut workers from its U.S. e-commerce unit across three rounds of layoffs since April, Bloomberg reported last week, noting that TikTok has replaced some staff near Seattle with managers connected to China. 'As the TikTok Shop business evolves, we regularly review our operations to ensure long-term success,' a spokesperson with TikTok said in a statement to GeekWire. 'Following careful consideration, we've made the difficult decision to adjust parts of our team to better align with strategic priorities.' TikTok Shop is TikTok's fastest-growing business, according to Bloomberg, though it has fallen short of recent internal sales targets. TikTok is planning to roll out a new version of its app for users in the U.S. ahead of a planned sale of TikTok's U.S. operations, The Information reported on Sunday. ByteDance is one of more than 100 out-of-town tech companies that have engineering centers in the Seattle region, as tracked by GeekWire.
Yahoo
25 minutes ago
- Yahoo
Tubi Hires Two Snap Inc. Alums For Key Ad Sales Positions
Tubi has hired Snap Inc. and Viacom alums Sharon Silverstein and Katelyn Kroneman for key ad sales exec posts. Silverstein is joining the Fox Corp. free streaming service as SVP, Head of U.S. Industry Verticals. During her 8-plus years at Snap, she was VP of North America Sales. Prior to that, she spent nearly 10 years at Viacom, rising to an SVP position at Nickelodeon. More from Deadline Tubi Rescues 'Demascus': Sci-Fi Comedy Series To Launch On Free Streamer Two Years After Being Pulled By AMC 'Ginny & Georgia' Dominates Nielsen Charts With Season 3 Premiere; 'The Accountant 2' Intrigues Audiences 'Squid Game' Season 3 Concludes Korean Series' Stunning Run With Another Netflix Viewership Record At Tubi, the L.A.-based executive will oversee all category leads across industry verticals and team with regional leadership. The Chicago-based Kroneman is coming aboard Tubi as VP of the finance and quick-serve restaurant ad categories. During her Snap tenure, which lasted more than nine years, Kroneman reached the position of Head of Verticals. Prior to Snap, she spent more than 11 years at Viacom (which merged with CBS Corp. to form Paramount Global), rising to VP. During her career, Kroneman has attained experience in a categories like consumer packaged goods, restaurants, financial services, telecom, entertainment, travel, automotive, and government/politics. It has already been a banner year for Tubi. In February, its livestream of the Super Bowl helped the game set all-time viewership records. Last month, the service announced it had surpassed 100 million monthly active users. Nielsen's monthly Gauge report has pegged it at about 2.2% of monthly TV viewing, ranking it behind only YouTube and Roku among free streaming outlets. On the ad front, Chief Revenue Officer Jeff Lucas (who himself worked at both Snap and Viacom) has implemented a strategy focused on verticals. The idea is to tailor ad packages to the individual needs and requirements of individual industry sectors. 'We know the one-size-fits-all approach doesn't work,' Lucas said in a statement. 'Sharon and Katelyn bring strategic vision and deep client expertise that will help us collaborate more closely with partners, creating bespoke solutions that drive results.' Best of Deadline 2025-26 Awards Season Calendar: Dates For Tonys, Emmys, Oscars & More 2025 TV Cancellations: Photo Gallery 'Poker Face' Season 2 Guest Stars: From Justin Theroux To Jason Ritter
Yahoo
25 minutes ago
- Yahoo
Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat)
EKTERLY is an FDA-approved oral therapy for the on-demand treatment of hereditary angioedema (HAE) ELK GROVE VILLAGE, Ill., July 7, 2025 /PRNewswire/ -- Orsini, a leader in rare disease pharmacy solutions, has been chosen by KalVista Pharmaceuticals as a specialty pharmacy partner for EKTERLY® (sepiapterin), an FDA-approved oral therapy for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. Read the full Prescribing Information here. HAE is a life-threatening inherited genetic disorder that can affect the autoimmune system, causing recurrent episodes of severe swelling, most commonly in the limbs, face, intestines and airway. The condition is a result of low levels or improper functioning of a protein called C1 inhibitor. While minor trauma or stress could trigger an attack, swelling often occurs without a known trigger. EKTERLY is administered at the onset of an HAE attack to quickly relieve symptoms and reduce the severity and duration of the episode. It is the tenth HAE therapy to join Orsini's portfolio. "Orsini has been a leader in the HAE space for over 14 years, and we are deeply committed to giving patients the care they need to overcome the day-to-day struggles they face," Darin DeCarlo, Orsini's Chief Commercial Officer, said. "It's our mission to ensure that no patient gets left behind, so we're thrilled to have another way to serve the HAE community with EKTERLY." About OrsiniProviding patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary treatments for rare diseases. Through integrated rare disease pharmacy solutions including pharmacy distribution, patient services, clinical management and convenient home infusion services, Orsini simplifies how patients connect to advanced therapies. Orsini's high-touch care model centers on experienced and trained therapy care teams that provide personalized patient care to ensure that No Patient is Left Behind™. Orsini holds accreditations with the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC and NABP. Orsini has earned URAC's Rare Disease Pharmacy Center of Excellence Designation and ACHC's Distinction in Rare Diseases and Orphan Drugs. For more information, visit View original content to download multimedia: SOURCE Orsini Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
